IP Library Granted Patent US 8,968,465
Granted Patent B2
US 8,968,465 · App. 14/156,850 · Granted Mar 3, 2015

Bone graft substitute composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,968,465
App. No.
14/156,850
Granted
Mar 3, 2015
Kind
B2
Abstract

A composition includes calcium sulfate hemihydrate, stearic acid, an accelerant, and a mixing solution. The composition can be injected, e.g., through a needle, and is capable of setting, e.g., in vivo, in a relatively short period of time to a relatively high hardness.

Claims (20)

1. A bone graft substitute composition kit, comprising: a powder mixture comprising greater than about 90 weight percent calcium sulfate hemihydrate, an accelerant for accelerating conversion of calcium sulfate hemihydrate to calcium sulfate dihydrate, the accelerant present in an amount of less than about 0.5 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.0 percent by weight of the powder mixture; an aqueous mixing solution; and an additional component selected from the group consisting of antiviral agents, antimicrobial agents, antibiotic agents, surface-active agents, antitumor agents, demineralized bone matrix, mesenchymal stem cells, bone marrow, growth factors, calcium phosphate materials, sodium bicarbonate, bone allograft, cancellous bone chips, pellets of calcium sulfate, and mixtures thereof.

2. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises greater than about 95 weight percent calcium sulfate hemihydrate.

3. The bone graft substitute composition kit of claim 1 , wherein the aqueous mixing solution is a saline solution.

4. The bone graft substitute composition kit of claim 1 , wherein the aqueous mixing solution comprises at least one inorganic salt or at least one cationic surface-active agent.

5. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises about 0.1 to about 0.5 weight percent of said accelerant.

6. The bone graft substitute composition kit of claim 1 , wherein the powder mixture comprises about 1.0 to about 2.0 weight percent of stearic acid.

7. The bone graft substitute composition kit of claim 1 , wherein the bone graft substitute composition produced by mixing said powder mixture and said aqueous mixing solution has a Vicat set time of about 5 to about 10 minutes.

8. The bone graft substitute composition kit of claim 1 , wherein the accelerant is present in an amount of about 0.1 to about 0.5 weight percent, and the stearic acid is present in an amount of about 1.0 to about 2.0 weight percent.

9. The bone graft substitute composition kit of claim 1 , wherein the accelerant is present in an amount of less than about 0.3 percent by weight of the powder mixture, and stearic acid in an amount of at least about 1.5 percent by weight of the powder mixture.

10. The bone graft substitute composition kit of claim 1 , wherein the accelerant is selected from calcium sulfate dihydrate and calcium sulfate dihydrate coated with sucrose.

11. The bone graft substitute composition kit of claim 1 , wherein the accelerant is calcium sulfate dihydrate coated with sucrose.

12. The bone graft substitute composition kit of claim 1 , wherein the bone graft substitute composition produced by mixing said powder mixture and said aqueous mixing solution is injectable through a needle.

13. The bone graft substitute composition kit of claim 1 , wherein the bone graft substitute composition kit further comprises sodium bicarbonate and the bone graft substitute composition produced by mixing said powder mixture and said aqueous mixing solution has a porous structure.

14. The bone graft substitute composition kit of claim 1 , wherein the additional component comprises demineralized bone matrix.

15. The bone graft substitute composition kit of claim 1 , wherein the additional component comprises an antibiotic agent.

16. The bone graft substitute composition kit of claim 15 , wherein the antibiotic is selected from the group consisting of tetracycline hydrochloride, vancomycin, cephalosporins, tobramycin, and gentamicin.

17. The bone graft substitute composition kit of claim 1 , wherein the additional component comprises a growth factor.

18. The bone graft substitute composition kit of claim 17 , wherein the growth factor is selected from the group transforming growth factor beta, bone morphogenic protein, basic fiberblast growth factor, and platelet-derived growth factor.

19. The bone graft substitute composition kit of claim 1 , wherein the additional component comprises an antitumor agent.

20. The bone graft substitute composition kit of claim 1 , wherein the additional component comprises a calcium phosphate material.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: MIDCAP FUNDING IV TRUST
To: WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.; ORTHOPRO, L.L.C.; SOLANA SURGICAL, LLC; TORNIER US HOLDINGS, INC.; TORNIER, INC.; TROOPER HOLDINGS INC.; WHITE BOX ORTHOPEDICS, LLC; WRIGHT MEDICAL CAPITAL, INC.; WRIGHT MEDICAL TECHNOLOGY, INC.; WRIGHT MEDICAL GROUP INTELLECTUAL PROPERTY, INC.
Reel/Frame 054480/0001 →
SECURITY INTEREST Recorded Jan 5, 2017
From: WRIGHT MEDICAL TECHNOLOGY, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 041257/0126 →